SEC Form 4 · accession 0001225208-17-002445
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J Holston
Officer — EVP, General Counsel
Period of report
Feb 3, 2017
Accepted (ET)
Feb 6, 2017 · 3:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 3, 2017 | M | 41,279 | $59.86 | A | 105,559 | D | |
| Common Stock | Feb 3, 2017 | M | 36,680 | $58.22 | A | 142,239 | D | |
| Common StockF1 | Feb 3, 2017 | S | 14,000 | $63.6904 | D | 128,239 | D | |
| Common StockF2,F3 | Feb 3, 2017 | S | 77,959 | $64.0027 | D | 50,280 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $59.86 | Feb 3, 2017 | M | 41,279 | D | May 1, 2016 | Apr 30, 2025 | Common Stock | 41,279 | 82,560 | D |
| Stock Option (right to buy)F5 | $58.22 | Feb 3, 2017 | M | 36,680 | D | May 9, 2015 | May 8, 2024 | Common Stock | 36,680 | 18,341 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.5100 to $63.8900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.0000 to $64.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F3Holdings include shares acquired in dividend reinvestment transactions.
- F4The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.
- F5The option became exercisable in equal installments on 5/9/2015, 5/9/2016 and 5/9/2017.